The Open Payments database at the Centers for Medicare & Medicaid Services continues to shine a bright light on the association between industry payments to physicians by drug and medical device companies and prescribing. In this issue of JAMA Internal Medicine, 2 Research Letters examine the association between these payments and physician prescribing in diverse fields—biologic medications for inflammatory bowel diseases1 and gabapentinoids for various conditions, including seizure disorders and postherpetic neuralgia.2